The seventh Liver Forum was held on October 19, 2017 in Washington, D.C.
271 people attended Liver Forum 7. Of those, 189 people attended in-person, and 82 people registered for the webcast.

Materials

• Agenda
• Participant List
• Meeting Summary 

Presentations

Session I: Liver Forum Overview

• Introduction & Liver Forum Updates
  Katherine Greene, Forum for Collaborative Research
• Regulatory Perspective Updates:
  
  1. FDA Introductory Remarks
  Lara Dimick-Santos, CDER, U.S. Food and Drug Administration
  
  2. The Liver Forum: Regulatory update from Europe
  Elmer Schabel, European Medicines Agency
  
  3. FDA/CDRH perspectives on validation of IVD biomarkers 
  Irene Tebbs, CDRH, U.S. Food and Drug Administration
  
  4. FDA/CDRH perspectives on imaging biomarkers: technical performance and analytical validation
  Dan Krainak, CDRH, U.S. Food and Drug Administration

Session II: Defining Endpoints for Advanced Disease

• Compensated Cirrhosis & Clinically Meaningful Benefit
  Naga Chalasani, Indiana University School of Medicine
  
• Cirrhosis Endpoints: ACLF and MELD 
  Rajiv Jalan, University College London
• Decompensated Cirrhosis: Endpoints and Experience in U.S. Phase 2B/3 Trials
  Arun Sanyal, Virginia Commonwealth University
  

Session III: U.S. Payer and Care Delivery Perspectives

• Medicare Coverage: A Review
  Louis Jacques, ADVI
  

Session IV: Working Groups

• Case Definitions Working Group
  Brent Tetri, Saint Louis University
  Sophie Megnien, Genfit
• Pediatric Issues Working Group
  Miriam Vos, Emory University
• Placebo Arm Data Working Group
  Eric Lefebvre, Allergan
• Standard of Care Working Group
  Manal Abdelmalek, Duke University
  Sven Francque, Antwerp University Hospital